miR-107 Activates ATR/Chk1 Pathway and Suppress Cervical Cancer Invasion by Targeting MCL1

Cheng-yan, Zhou; Li, Gang; Zhou, Jingjing; Han, Na; Liu, Zhihui; Yin, Jun

doi:10.1371/journal.pone.0111860

Cited by 46 publications

(36 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, enhanced miR-125 expression was shown to reduce MCL1 expression and inhibit invasion of a human gastric cancer cells (54). Similarly, targeting of MCL1 by miR-107 was shown to abrogate invasion of cervical cancer-derived SiHa and HeLa cell lines (55), and miR-133b was shown to knockdown MCL1 expression in two osteosarcoma cell line lines, thereby reducing their invasive capacity in vitro (56). Therefore, these MCL-1-targeting miRNAs are interesting candidates to be validated for their modulating effects on MCL1 expression also in melanoma cells.…”

Section: Discussionmentioning

confidence: 92%

miR-339-3p Is a Tumor Suppressor in Melanoma

et al. 2016

View full text Add to dashboard Cite

Determinants of invasion and metastasis in cancer remain of great interest to define. Here, we report the definition of miR-339-3p as a novel tumor suppressive microRNA that blocks melanoma cell invasion without affecting cell survival. miR-339-3p was identified by a comprehensive functional screen of a human miRNA mimetic library in a cell-based assay for invasion by the melanoma cell line A375. miR-339-3p was determined as a strong inhibitor of invasion differentially expressed in melanoma cells and healthy melanocytes. MCL1 was defined as a target for downregulation by miR-339-3p, functioning through direct interaction with the 3 0 untranslated region of MCL1 mRNA. Blocking miR-339-3p by an antagomiR was sufficient to increase melanoma cell invasion, an effect that could be phenocopied by RNAi-mediated silencing of MCL1. In vivo studies established that miR-339-3p overexpression was sufficient to decrease lung colonization by A375 melanoma cells in NSG mice, relative to control cells. Overall, our results defined miR-339-3p as a melanoma tumor suppressor, the levels of which contributes to invasive aggressiveness.

show abstract

Section: Discussionmentioning

confidence: 92%

miR-339-3p Is a Tumor Suppressor in Melanoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Regarding the function of miR-107 in cancer, reduced miR-107 expression has been reported in various types of cancer [69][70][71][72][73][74][75][76][77][78] , and several recent studies have identified the tumor suppressor functions of miR-107. One crucial function of miR-107 that has been identified is the inhibition of oncogenes, such as CDK8 in breast cancer 71 , the ATR/Chk1 pathway in cervical cancer 79 , HIF-1, CCND1, and NFKB1 in colon cancer 80,81 , CDK in gastric cancer 70 , CDK6, Notch-2, and VEGF in glioma Expression profiles of miR-107 in human organs. To gain insight into the systemic secretion of miR-107 from normal healthy cells, we examined the expression profiles of miR-107 in human organs.…”

Section: Discussionmentioning

confidence: 99%

Depleted Tumor Suppressor miR-107 in Plasma Relates to Tumor Progression and Is a Novel Therapeutic Target in Pancreatic Cancer

Imamura

Komatsu

Ichikawa

et al. 2017

Journal of the American College of Surgeons

View full text Add to dashboard Cite

This study explored decreased tumor suppressor microRNA (miRNA) plasma levels in pancreatic cancer (PCa) patients to clarify their potential as novel biomarkers and therapeutic targets. We used the microRNA array-based approach to select candidates by comparing plasma levels between PCa patients and healthy volunteers. Six down-regulated miRNAs (miR-107, miR-126, miR-451, miR-145, miR-491-5p, and miR-146b-5p) were selected. Small-and large-scale analyses using samples from 100 PCa patients and 80 healthy volunteers revealed that miR-107 was the most down-regulated miRNA in PCa patients compared with healthy volunteers (P < 0.0001; area under the receiver-operating characteristic curve, 0.851). A low miR-107 plasma level was significantly associated with advanced T stage, N stage, and liver metastasis and was an independent factor predicting poor prognosis in PCa patients (P = 0.0424; hazard ratio, 2.95). miR-107 overexpression in PCa cells induced G1/S arrest with the production of p21 and inhibited cell proliferation through the transcriptional regulation of Notch2. In vivo, the restoration and maintenance of the miR-107 plasma level significantly inhibited tumor progression in mice. Depletion of the tumor suppressor miR-107 in plasma relates to tumor progression and poor outcomes. The restoration of the plasma miR-107 level might be a novel anticancer treatment strategy for PCa.Pancreatic cancer (PCa) is the fourth leading cause of cancer-related death in Japan and the United States 1 and the seventh worldwide 2 . PCa is one of the most aggressive cancer types and constitutes a global health problem, with more than 330,000 cancer-related deaths annually 2 . Although perioperative chemo-and/or radiotherapy regimens, surgical techniques and perioperative management have greatly progressed, PCa continues to present an extremely poor prognosis. Even now, the median survival time of PCa patients is 5 to 8 months, and their 5-year survival rate is less than 10%. This is because PCa develops with no symptoms, local invasiveness, or metastases to distant organs in the early stage of its clinical course [3][4][5] . Therefore, novel early diagnostic tools and effective treatment strategies are urgently needed to improve the survival rate of PCa patients.Because understanding the molecular mechanisms of tumorigenesis and identifying clinical biomarkers and molecular targets for PCa contribute to improving the management of this lethal disease, several studies have attempted to detect the biological factors involved in the malignant potential of PCa 6, 7 . Nevertheless, in clinical settings, no molecule has been used as an early diagnostic biomarker, and only a few molecules have been

show abstract

“…Growing evidence has demonstrated that numbers of miRNAs are crucial for the initiation, progression and metastasis of cervical cancer by regulating various processes, including cancer cell proliferation, differentiation, apoptosis, adhesion, cell cycle arrest, migration and invasion (11,24,25). For instance, Zhou et al (26) demonstrated that that miR-107 directly targeted myeloid cell leukemia-1 and activated the ATR serine/threonine kinase/checkpoint kinase 1 pathway to inhibit the proliferation, migration and invasiveness of cervical cancer cells. Li et al (27) reported that the overexpression of miR-342-3p inhibits cell proliferation, migration and invasion in cervical cell lines by targeting mammalian transcription factor forkhead box M1.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-138 inhibits proliferation, migration and invasion through targeting hTERT in cervical cancer

et al. 2016

View full text Add to dashboard Cite

Abstract.A growing body of evidence suggests that microRNA-138 (miR-138) functions as a tumor suppressor, and is involved in tumor initiation, development and metastasis in certain types of human cancers. However, the function and underlying molecular mechanism of miR-138 in cervical cancer remains unclear. Therefore, the purpose of the present study was to investigate the clinical significance of miR-138 expression in cervical cancer, and to evaluate its role and underlying mechanisms in cervical cancer. The present study indicated that miR-138 expression was significantly downregulated in cervical cancer tissues and cell lines, and that the low miR-138 expression was negatively associated with advanced FIGO stage and lymph node metastasis (P<0.01). Functional analyses indicated that the overexpression of miR-138 in cervical cancer cells inhibited cell proliferation, migration and invasion, induced cell apoptosis in vitro, and suppressed tumor growth in a nude mice model. Luciferase reporter assays confirmed that human telomerase reverse transcriptase was a novel target gene of miR-138. The findings of the present study suggested that miR-138 could be a potential candidate for cervical cancer therapeutics.

show abstract

miR-107 Activates ATR/Chk1 Pathway and Suppress Cervical Cancer Invasion by Targeting MCL1

Cited by 46 publications

References 22 publications

miR-339-3p Is a Tumor Suppressor in Melanoma

miR-339-3p Is a Tumor Suppressor in Melanoma

Depleted Tumor Suppressor miR-107 in Plasma Relates to Tumor Progression and Is a Novel Therapeutic Target in Pancreatic Cancer

MicroRNA-138 inhibits proliferation, migration and invasion through targeting hTERT in cervical cancer

Contact Info

Product

Resources

About